Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of CAM2038 in Opioid Use Disorder
NCT02672111Phase 3Completed
- Sponsor
- Braeburn Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 3 trial of buprenorphine in opioid use disorder (OUD), sponsored by Braeburn Pharmaceuticals. Started Nov 2015; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02672111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672111.